Navigation Links
Schering-Plough Reports Financial Results for Third Quarter of 2008
Date:10/21/2008

------------------

Net sales, as reported a/ $14,154 $8,965 58%

50 percent of cholesterol joint

venture net sales b/ 1,719 1,838 (6%)

Adjusted net sales b/ $15,873 $10,803 47%

a/ Net sales for the three and nine months ended September 30, 2008

include sales from Organon BioSciences (OBS) which was acquired on

November 19, 2007.

b/ Total Net sales of the cholesterol joint venture for the three months

ended September 30, 2008 and 2007 were $1.1 billion and $1.3 billion,

respectively. Total Net sales of the cholesterol joint venture for the

nine months ended September 30, 2008 and 2007 were $3.4 billion and $3.7

billion, respectively.

NOTE: Adjusted net sales, defined as net sales plus an assumed 50 percent

of global cholesterol joint venture net sales, is a non-U.S. GAAP measure

used by management in evaluating the performance of the Schering-Plough's

overall business. Schering-Plough believes that this performance measure

contributes to a more complete understanding by investors of the overall

results of the company. Schering-Plough provides this information to

supplement the reader's understanding of the importance to the company of

its share of results from the operations of the cholesterol joint venture.

Net sales (excluding the cholesterol joint venture net sales) is required

to be presented under U.S. GAAP. The cholesterol joint venture's net sales

are included as a component of income from operations in the calculation

of Schering-Plough's "Equity income." Net sales of the cholesterol joint

venture do not include net sales of cholesterol products in non-joint

venture territories.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. Schering-Plough Announces Transition of Animal Health Leadership
2. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
3. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
4. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
5. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
6. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
7. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
8. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
9. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
10. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... has enough capacity for typical season; experts less sure about ... current swine flu outbreak is raising critical questions about the ... logistics of getting it to the people who need it. ... into this fall,s production of seasonal influenza vaccine, experts say. ...
... war, blast injuries have become the signature injuries. These ... cause damage to the visual system and the visual processing ... wrong with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, ... LAKE, N.Y., May 18 The journey home is a ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
... Preliminary results from the first-of-its-kind Clinical Evaluation and ... at the Society of Gastroenterology Nurses and Associates, Inc. ... The study indicated that while there are written endoscope ... in the study, significant variation in manual reprocessing takes ...
... Data on frequency of resistance development and safety ... Microbiology and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... best-in-class drugs for the treatment of serious bacterial ... of torezolid (TR-701), a novel antibiotic that is ...
... from Alcon and Initial Payments from New Galderma ... Calif., May 18 NovaBay Pharmaceuticals, Inc. (NYSE ... company developing first-in-class anti-infective products for the treatment ... without causing resistance, reported today its financial results ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 2Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 3Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 4Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9
(Date:1/22/2015)... Jan. 22, 2015  ViewRay™, a privately held medical device ... exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange ... for the treatment of cancer in Japan ... the world,s first and only MRI-guided radiation therapy system ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... Increasing sophistication among enterprise buyers of language services ... 2015, says Moravia CMO, Renato Beninatto ... market research firm Common Sense Advisory, 15 percent of ... and localization needs. "From a language industry perspective, this ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Dr. Michael Klein , director of the Food and Drug Administration (FDA) Controlled Substance ... abuse of prescription drugs.   , , , ... , , ... , , Learn more ...
... , July 28, 2010 , ... - Company Expands Market-leading Family of Neurovascular Stents , ... Boston Scientific Corporation (NYSE: BSX ... fourth-generation,intracranial aneurysm stent system designed for use in conjunction with,endovascular coiling to treat wide-necked ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D. 2Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 2Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 3Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: